APA (7th ed.) Citation

ZD, E., E, D., U, A., CL, B., P, C., A, D., . . . A, K. (2024). Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation. Haematologica, 109(4), 1149. https://doi.org/10.3324/haematol.2023.282898

Chicago Style (17th ed.) Citation

ZD, Epstein-Peterson, et al. "Immunochemotherapy Plus Lenalidomide for High-risk Mantle Cell Lymphoma with Measurable Residual Disease Evaluation." Haematologica 109, no. 4 (2024): 1149. https://doi.org/10.3324/haematol.2023.282898.

MLA (9th ed.) Citation

ZD, Epstein-Peterson, et al. "Immunochemotherapy Plus Lenalidomide for High-risk Mantle Cell Lymphoma with Measurable Residual Disease Evaluation." Haematologica, vol. 109, no. 4, 2024, p. 1149, https://doi.org/10.3324/haematol.2023.282898.